ArticlePloS one2024

Predictive immunoinformatics reveal promising safety and anti-onchocerciasis protective immune response profiles to vaccine candidates (Ov-RAL-2 and Ov-103) in anticipation of phase I clinical trials.

Derrick Neba Nebangwa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.